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Background: Several medication classes may contribute to urinary symptoms in older adults. The purpose of this
study was to determine the prevalence of use of these medications in a clinical cohort of incontinent patients.
Methods: A cross-sectional study was conducted among 390 new patients aged 60 years and older seeking care
for incontinence in specialized outpatient geriatric incontinence clinics in Quebec, Canada. The use of oral
estrogens, alpha-blocking agents, benzodiazepines, antidepressants, antipsychotics, ACE inhibitors, loop diuretics,
NSAIDs, narcotics and calcium channel blockers was recorded from each patient’s medication profile. Lower urinary
tract symptoms and the severity of incontinence were measured using standardized questionnaires including the
International Consultation on Incontinence Questionnaire. The type of incontinence was determined clinically by a
physician specialized in incontinence. Co-morbidities were ascertained by self-report. Logistic regression analyses
were used to detect factors associated with medication use, as well as relationships between specific medication
classes and the type and severity of urinary symptoms.
Results: The prevalence of medications potentially contributing to lower urinary tract symptoms was 60.5%.
Calcium channel blockers (21.8%), benzodiazepines (17.4%), other centrally active agents (16.4%), ACE inhibitors
(14.4%) and estrogens (12.8%) were most frequently consumed. Only polypharmacy (OR = 4.9, 95% CI = 3.1-7.9), was
associated with medication use contributing to incontinence in analyses adjusted for age, sex, and multimorbidity.
No associations were detected between specific medication classes and the type or severity of urinary symptoms in
this cohort.
Conclusion: The prevalence of use of medications potentially causing urinary symptoms is high among incontinent
older adults. More research is needed to determine whether de-prescribing these medications results in improved
urinary symptoms.
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Lower urinary tract symptoms such as urinary frequency,
urgency, nocturia, urinary incontinence and voiding diffi-
culties are highly prevalent and bothersome, impair quality
of life and are associated with falls in the elderly [1-4].
The etiology of lower urinary tract symptoms may be
singular or multifactorial, with potential contributors
encompassing lifestyle habits, underlying bladder or
pelvic floor dysfunction, associated co-morbidities and/
or functional factors [5,6]. Many commonly used medi-
cations have been proposed to inadvertently interfere
with bladder and/or sphincter function, or indirectly im-
pair the ability to toilet [6,7]. The use of oral estrogens,
alpha-blocking agents, sedative-hypnotics, antidepressants,
antipsychotics, ACE inhibitors, loop diuretics, non-steroidal
anti-inflammatory agents (NSAIDS) and calcium channel
blockers have all been implicated to some degree in the
onset or exacerbation of urinary symptoms [8-23]. Stress
urinary incontinence has been associated with the use of
alpha-blocking agents, which reduce urethral sphincter
tone, and with consumption of ACE inhibitors in patients
who experience treatment-related cough [24,25]. Loop di-
uretics promote polyuria and can lead to urinary urgency
and frequency, while NSAIDS and other medications
known to cause edema may exacerbate nocturia due to
nocturnal fluid redistribution. Centrally active medication
potentially exert direct effects on the lower urinary tract
system by causing relaxation of striated pelvic floor
muscles and interfering with afferent sensory messages
from the bladder, or even indirectly through their effect
on mobility and toileting ability. Calcium channel blockers
have been associated with bladder relaxation and impaired
emptying, while the mechanism of action of estrogen re-
placement therapy remains unknown. Acetylcholinesterase
inhibitors can precipitate de novo urgency incontinence via
enhanced cholinergic activity in the bladder.
Elderly patients who seek care for incontinence have a
higher likelihood of multiple morbidity, functional impair-
ment and increased susceptibility to the adverse effects of
medications [6]. The prevalence of use of medications po-
tentially contributing to urinary symptoms in older adults
seeking care for incontinence remains unknown. A greater
understanding of the frequency of use of specific classes of
medications among these individuals could help target fu-
ture research studies and clinical care approaches for redu-
cing medication-risk in patients with urinary symptoms.
The purpose of the present report is to describe the
prevalence of use of medications potentially causing or
exacerbating lower urinary tract symptoms in a clinical
cohort of older men and women presenting to out-
patient incontinence clinics for an evaluation of urinary
incontinence. Secondary objectives were to determine
which factors were associated with the use of these med-
ications, and to investigate whether associations betweenspecific medication classes and the type or severity of
urinary symptoms could be detected.
Methods
Study design, setting and sample
A cross sectional study of incontinent men and women
aged 60 years and older was conducted in Quebec,
Canada. Participants were recruited from consecutive
new patients presenting to three outpatient urology
clinics and three geriatric outpatient incontinence clinics
in the Montreal and Sherbrooke areas of Quebec, Canada.
The method for recruiting patients has been described
previously [26]. Briefly, patients were included in the
cohort if they reported a weekly average of one or more
episodes of involuntary urine loss during the preceding
3 months. Patients with known dementia (a screening
Mini-Mental State Exam score ≤ 24) were excluded from
the cohort in order to avoid unreliable self-reported
measures. Ten patients with missing data or incomplete
medication information were excluded from the analyses.
All protocols and procedures were approved by the Insti-
tutional Ethics Review Boards of the Institut universitaire
de gériatrie de Montréal and the Institut universitaire de
gériatrie de Sherbrooke. Informed consent was obtained
from each participant prior to data collection.
Data collection and measurement
A research assistant recorded medication use from
bottle labels (or dosette boxes) for prescription drugs
and over-the-counter products at the time of the initial
clinic visit. Adherence was determined by asking pa-
tients if they were currently consuming each medication
as prescribed. The name of each prescribed medication,
the frequency, daily dose, and treatment duration were
recorded. Medications were coded according to the
Anatomical Therapeutic Classification [27] for users and
non-users of oral estrogens, alpha-blocking agents (anti-
hypertensive and prostate medications), benzodiazepines,
antidepressants, antipsychotics, ACE inhibitors, loop di-
uretics, NSAIDs, lithium, narcotics and calcium channel
blockers. Medications known to cause pedal edema such
as other GABAergic analgesics (gabapentin, neurontin)
and the thiazolinedione hypoglycemic agents were also
recorded. Local estrogen formulations were not consid-
ered in this analysis.
Storage lower urinary tract symptoms were queried by
self-report in accordance with definitions from the Inter-
national Continence Society [28]. Increased daytime
urinary frequency was defined as passing urine 8 or
more times per day. Participants reporting the need to
wake up at night more than once to urinate were
defined as having nocturia. Participants who reported a
feeling of urgency and having to rush to the toilet before
passing urine (occasionally, most of the time, or all of
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International Consultation on Incontinence Questionnaire-
ICIQ-UI-SF was used to determine the presence and
severity of urinary incontinence [29]. The severity score
for each patient was calculated as the sum of the first 3
items (frequency, amount and impact), ranging from 0
to 21 points. Three severity categories were created:
mild (0–5), moderate (6–12), and severe (13–21). The
type of incontinence was diagnosed by the treating
physician after performing a standard assessment in-
cluding history, physical examination, stress test, blad-
der ultrasound for post-void residual urine volume, and
urine analysis. A diagnosis of stress, urgency, mixed,
urgency with impaired bladder emptying, or functional
incontinence was relayed to the research team. Uro-
dynamic tests were not performed unless ordered by the
treating physician. Voiding symptoms were not system-
atically recorded and are not considered in this analysis.
Comorbidities and other socio-demographic variables
were self-reported by the participant to the research assist-
ant. Comorbidities were based on previous medical diag-
noses. Heart disease, stroke and peripheral vascular
disease were categorized together as cardiovascular dis-
eases. Musculoskeletal disorders included arthritis, osteo-
porosis and gout.
Statistical analyses
Descriptive statistics were used to characterize the partici-
pants and to determine the prevalence of use of each
medication type. Data were summarized by percentages
for categorical variables, and means (±standard deviations)
for continuous data. To investigate factors associated with
the use of medications contributing to lower urinary tract
symptoms, logistic regression analyses were conducted,
with medication use inserted in the model as the
dependent variable. Age (continuous), sex (binary), in-
dividual comorbid conditions (binary), multimorbidity
(≥ 3 conditions)29 and the presence of polypharmacy
(≥ 5 medications)30 were regressed against the use of
each medication class. Medications belonging to classes
presumed to contribute to urinary symptoms were ex-
cluded from the polypharmacy variable. To determine
whether associations could be detected between the type
or severity of lower urinary tract symptoms and the use of
drugs from specific medication classes, univariate and
multivariate analyses were conducted with the inde-
pendent variable coded as user versus non user of the
targeted medications potentially causing or exacerbating
lower urinary tract symptoms (e.g. oral estrogens, alpha-
blocking agents, sedative-hypnotics, antidepressants, anti-
psychotics, ACE inhibitors, loop diuretics, NSAIDS,
calcium channel blockers, and other GABAergic analge-
sics). The dependent variable was either the presence or
absence of each urinary symptom (urgency versus nourgency, nocturia versus nocturia); the type of incontin-
ence (e.g. stress versus other types, urge versus other
types); or the severity of incontinence (mild versus moder-
ate or severe). First we regressed “any” medication class as
the independent variable, then subgroup analyses were
conducted using each distinct medication class separately.
Age, sex, polypharmacy and other co-morbidities were in-
cluded in multivariate analyses if they were independently
associated with the outcome at p < 0.05. Results are
presented as odds ratio (OR) and 95% confidence intervals
(95% CI). All statistical analyses were conducted using
SPSS.
Results
Three hundred and ninety men and women consented
to enroll in the study over a four year time period,
representing approximately forty percent of all new pa-
tients. The most common reasons for refusing to partici-
pate were dementia, institutionalization, disinterest in
participating in a research study, and competing acute
illness. Data on eligible patients who refused to partici-
pate were not available for comparison. Only 1% of
interested individuals met exclusion criteria.
Table 1 shows the characteristics of the participants
and the distribution of urinary symptoms and types of
incontinence. The mean age was 72.4 ± 6.4 years (range
60–90), the mean number of co-morbid conditions was
5.0 ± 2.5, and patients consumed on average 6.2 ± 3.8 dif-
ferent medications. The most frequent co-morbid condi-
tions included musculoskeletal disorders (self-reported
arthritis symptoms), dyslipidemia and depression. All pa-
tients were incontinent; the majority (93.1%) reported
moderate to severe symptoms. Forty-five percent of
patients were diagnosed with urgency incontinence as
the primary diagnosis, explaining the high prevalence of
other overactive bladder symptoms such as urinary
frequency (78.7%), urgency (91.8%) and nocturia (83.6%)
in the cohort.
The prevalence of use of medications potentially con-
tributing to urinary symptoms was 60.5% (n = 236), with
a mean of one incriminating drug per patient (Table 2).
The top five medication classes were calcium channel
blockers (21.8%), benzodiazepines (17.4%), other cen-
trally active agents including antipsychotics, antidepres-
sants and narcotics (16.4%), ACE inhibitors (14.4%) and
oral estrogens (12.8%). Use of loop diuretics and alpha-
blocking antihypertensive agents was rare.
Polypharmacy was the only factor associated with the
use of medications potentially contributing to incontin-
ence in multivariate analysis (Table 3). Individuals con-
suming 5 or more drugs were almost 5 times more likely
to be taking a medication contributing to urinary symp-
toms, when adjusting for age, sex and comorbidity
(OR = 4.9, 95% CI = 3.1-7.9). Multimorbidity, cardiovascular
Table 1 Patient characteristics and distribution of urinary
symptoms (n = 390)
Characteristics Number (%)









Cardiovascular disease 133 (34.1%)
Depression 142 (36.4%)
Respiratory disease 65 (16.7%)
Renal failure 20 (5.1%)
Musculoskeletal disorders 385 (98.7%)











Other lower urinary tract symptoms
Urinary frequency 307 (78.7%)
Urinary urgency 358 (91.8%)
Nocturia 326 (83.6%)
Table 2 Prevalence of use of medications potentially
contributing to urinary symptoms (n = 390)
Medication class Prevalence n (%)
Any medication class 236 (60.5%)
Calcium channel blockers 85 (21.8%)
Benzodiazepines 68 (17.4%)
Other centrally active agents* 65 (16.7%)
ACE inhibitors 56 (14.4%)
Oral estrogens 50 (12.8%)
Oral estrogen + progesterone 12 (3.1%)
NSAIDS 38 (9.7%)
GABAergic analgesics 11 (2.8%)
Loop diuretics 7 (1.8%)
Thiazolinedione hypoglycemic agents 3 (0.8%)
Alpha blocking antihypertensives 1 (0.3%)
*Antidepressants, antipsychotics and narcotics were combined.
Table 3 Factors associated with the use of medications
potentially causing urinary symptoms
Predictor Crude odds ratio Adjusted odds ratio*
(95% CI) (95% CI)
Age 1.0 (1.0 - 1.1) 1.0 (1.0 - 1.1)
Sex 1.5 (0.7 - 3.0) 1.1 (0.5 - 2.3)
Polypharmacy (≥ 5 drugs) 5.3 (3.4 – 8.2) 4.9 (3.1 – 7.9)
Multimorbidity (≥ 3) 2.0 (1.2 - 3.3) 1.2 (0.6 – 2.03)
Depression 1.1 (0.7 - 1.67) 0.7 (0.4 - 1.2)
Cardiovascular disease 2.0 (1.3 - 3.0) 1.4 (0.8 - 2.3)
Hypertension 2.2 (1.4 - 3.5) 1.5 (0.9 - 2.7)
Respiratory disease 1.7 (1.0 - 3.1) 1.4 (0.7 - 2.9)
Gastrointestinal disorders 1.5 (1.0 - 2.2) 1.1 (0.6 - 1.9)
Dyslipidemia 1.6 (1.1 - 2.4) 0.9 (0.5 - 1.5)
Renal failure 1.6 (0.6 - 4.1) 0.7 (0.2 - 2.1)
Musculoskeletal disorders 1.3 (1.0 - 1.6) 0.9 (0.6 - 1.2)
Diabetes 1.4 (0.9 - 2.3) 0.9 (0.5 - 1.7)
*Adjusted for age, sex, polypharmacy and multimorbidity.
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with medication use in univariate models but did not re-
main significant in adjusted models. No associations were
found between age or sex and the use of medications po-
tentially contributing to urinary symptoms.
Regression analyses failed to detect significant associa-
tions between urinary frequency, urgency or nocturia
with any medication class. Nor was any association
found between the class of medication and the type or
severity of incontinence in univariate or multivariate
models adjusted for age, sex, polypharmacy and multiple
morbidity (data not shown).
Discussion
The prevalence of use of medications potentially con-
tributing to urinary symptoms was high (60.5%) among390 new patients presenting for evaluation to a geriatric
incontinence clinic. The most common medication classes
were calcium channel blockers, benzodiazepines, other
centrally active agents, ACE inhibitors and oral estrogens.
Loop diuretics and alpha-blocking agents were less fre-
quently prescribed. Patients with polypharmacy were five
times more likely to consume potentially deleterious med-
ications, regardless of age, sex and multimorbidity. No
specific disease state was associated with medication use
when polypharmacy was accounted for. Our analyses were
unable to detect significant associations between specific
medication classes and the type or severity of lower urin-
ary tract symptoms.
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tween specific medication classes thought to precipitate
symptoms and the type or severity of symptoms mirrors
the negative results reported from other large epidemio-
logical studies that examined the relationship between
current medication use and urinary incontinence, such
as the Boston Area Community Health Survey and the
Health, Aging and Body Composition Study [10,21]. One
explanation is the cross-sectional nature many of these
analyses. Studies that do not account for the timing of
administration of a new drug in relation to the appear-
ance of urinary symptoms are limited in their ability to
establish causality. Criteria for causality require that the
cause precede the effect [30,31]. To meet this criterion,
neither incontinence nor the use of a medication class
thought to contribute to urinary symptoms should be
present at the onset of the study in the population of
interest. Observational studies that aim to investigate
the effect of specific medication classes on the occur-
rence and type of urinary symptoms in subgroups of
healthy and frail individuals should employ a new-user
cohort of individuals without previous medication use or
urinary symptoms, rigorous ascertainment of incident
incontinence, and sensitive markers of frailty [32]. The
strength of the association and the specificity of differ-
ent treatment-emergent harmful effects in elderly indi-
viduals may vary according to whether individuals are
healthy, frail or pre-frail, and whether more than one
urinary symptom develops. The risk of adverse out-
comes may therefore depend on the presence of mul-
tiple risk factors and these should be accounted for in
the analysis.
Despite this research complexity, a growing body of
evidence supports clinicians in their efforts to pursue
medication modification as a risk reduction strategy for
patients experiencing urinary symptoms. Data exist on
post-menopausal hormone therapy examined in the con-
text of two large randomized placebo controlled trials,
with urinary symptoms as a post-hoc endpoint [8,9].
Findings indicated a two-fold increased risk of de novo
stress and mixed incontinence among new users of es-
trogen replacement therapy [8], a 30% increase in the
onset of urgency incontinence [8] and a significant ex-
acerbation in the amount and frequency of stress and ur-
gency incontinence among women with pre-existing
symptoms [8,9]. In a case control study, 20/49 women
taking alpha-blocking antihyperstensives experienced in-
continence compared to 8/49 controls (40.8 vs. 16.3%),
although the relationship no longer persisted when pa-
tients on loop diuretics were excluded from the analysis
[12]. Discontinuation of alpha-blocking agents in 18
women with incontinence resulted in 13 (72%) reporting
total or almost complete resolution of their urinary
symptoms [12]. Clinical data from a series of 172 elderlyhypertensive and heart failure patients found that the
use of loop but not thiazide diuretics was significantly
associated with increased urinary frequency, a relation-
ship that persisted when the age of the patient and the
use of other cardiovascular diseases were accounted for
[16]. New use of calcium channels blockers among 38
men aged 47–89 years old was found to significantly
exacerbate voiding symptoms, even when adjusting for
other medication use and conditions that could contribute
to lower urinary tract symptoms [23]. A number of case
reports describe cough-induced stress incontinence upon
initiation of an ACE inhibitor, which remits upon discon-
tinuation, and one case series reported a 10% incidence of
severe ACE-inhibitor-induced stress incontinence in
diabetic post-menopausal women [17,24,25].
The prevalence of use of medications potentially affec-
ting lower urinary tract symptoms may be underestimated
in the current study due to selection bias. Patients with
dementia, residents of nursing homes, and acutely ill
patients did not participate, and may reasonably have a
higher risk of taking acetylcholinesterase inhibitors or
consuming multiple medications. Furthermore, the cohort
comprised a select sample of patients who were referred
to a specialist clinic, and only 40% of eligible patients
consented to provide data. Women were over-
represented. Many patients are referred to subspecialty
clinics only when their symptoms are refractory to first-
line management, so medications contributing to urin-
ary symptoms already may have been discontinued. Pa-
tients successfully treated by a primary care provider by
stopping a medication (e.g., a diuretic), would not be re-
ferred to the incontinence clinic and would not be in-
cluded in the current sample. Multimorbidity was not a
significant predictor when polypharmacy was accounted
for, and this could partially be explained by collinearity
between the two variables, or by virtue of polypharmacy
acting as a proxy of disease severity. Although an at-
tempt was made to investigate the association between
medication usage and the type of incontinence, the eti-
ology of incontinence is often multifactorial in older
persons, so misclassification or lack of specificity of the
type of incontinence may have contributed to the null
effect of these analyses.
Conclusion
The prevalence of use of medications potentially causing
or exacerbating lower urinary tract symptoms was high
(60.5%) in this clinical cohort of new patients presenting
for a geriatric evaluation of urinary incontinence. More
research is needed to determine whether de-prescribing
these medications results in improved urinary symptoms.
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